top of page

General Critical Care

Public·598 members

Are you still using high dose steroids in nonresolving ARDS in Critically Ill COVID-19 Patients Treated with Dexamethasone?

  • Yes

  • No

  • Sometimes

The objective of the study was to determine the impact of high doses of corticosteroids (equal or greater than 1 mg/kg of methylprednisolone: HDCT) in critically ill COVID-19 patients with nonresolving acute respiratory distress syndrome (ARDS) previously treated with dexamethasone.

  • Prospective observational cohort study of patients with nonresolving ARDS related to COVID-19. Comparing those who received HDCT with those who did not. Primary outcome: 90-day mortality.

  • 11 ICUs in the Great Paris area from September 2020 to February 2021.

  • 383 patients included (59 in HDCT group, 324 in no HDCT group).

  • At day 90, 51% of HDCT group and 35.8% of no HDCT group patients had died. HDCT was significantly associated with higher 90-day mortality.

🔍 Summary: High doses of corticosteroids (HDCT) in critically ill COVID-19 patients with nonresolving ARDS, previously treated with dexamethasone, were linked to a higher 90-day mortality rate. However, HDCT did not increase the risk of ventilator-associated pneumonia.

High-Dose Steroids for Nonresolving Acute Respiratory Distre... : Critical Care Medicine (

bottom of page